Outcomes4Me Secures $21M Funding Round
				
				
			  
			
			 2025-05-29
			
			
			
			
              
			  
			
			
			
			BOSTON, MA, Outcomes4Me, the developer of the leading direct-to-patient, AI-driven platform transforming the cancer care experience, today announced the close of a $21 million funding round.			
			 
                  
                  With this round, Outcomes4Me welcomes new investor London-based Salica Investments, with participation from all existing investors: Labcorp Venture Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Management Ventures, IRA Capital, and Merstal LTD, bringing Outcomes4Me's total capital raised to date to $38M.
Outcomes4Me is the first and only end-to-end, AI-driven patient empowerment platform that helps patients with cancer take a proactive approach to their care from diagnosis throughout every stage of life and care. Its direct-to-patient platform integrates clinical guidelines, genomics, trial matching, and symptom tracking to help patients navigate through a cancer diagnosis with confidence and clarity. Through its patented technology, Outcomes4Me is redefining cancer care by delivering smarter, AI-powered solutions that put patients in control of their treatment decisions. What sets Outcomes4Me apart is its ability to generate unique, at-scale proprietary datasets that enable more precise and actionable insights for better patient outcomes. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer and technology veterans. For more information, visit www.outcomes4me.com.
				  
				  (c) by Massinvestor, Inc.  For contact info, please check out our 
about page.
 
			  
                  >> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors